




Two therapies.
One circuit.
Zero compromise.




The **AirSpiral 2-in-1** circuit allows you to seamlessly switch between NIV and NHF while delivering clinically required levels of humidity with less condensate.*

Therapy flexibility for NHF and NIV

No matter how you want to use NHF and NIV, AirSpiral 2-in-1 gives you ease of use because you don't need to change circuits.

NHF



NIV



Why delivery of Optimal Humidity is important for NHF


Optimal Humidity is the condition in which our airways naturally heat and humidify inspired gas - normally reaching 37 °C and 44 mg/L H₂O (body temperature and pressure, saturated, or BTPS).

Heated, humidified gases are integral to enabling the high flow rates for nasal high flow (NHF) therapy. A dew-point setting of 37 °C is considered the standard setting for NHF (as evidenced by clinical research³⁻¹¹).

This humidification level assists in the comfortable delivery of NHF therapy and helps to emulate the natural balance of heat and humidity in the respiratory system, as well as to support mucociliary clearance.

The AirSpiral 2-in-1 has been designed to deliver the clinically required level of humidity so your patients can experience these benefits.

AirSpiral 2-in-1 technology



Less Condensate

AirSpiral 2-in-1 technology produces up to 80% less condensate and 20% more humidity. *

Less condensate reduces therapy interruption due to "rainouts".

The insulated pockets of air and integrated wall heating along the length of the circuit protect humidified gases from ambient conditions, resulting in less condensate and more humidity during noninvasive (NIV) and NHF therapy.*



Patient Comfort

Small and light.

The AirSpiral 2-in-1's smoothbore internal walls enable the design of a smaller diameter tubing and reduces resistance to flow during NIV. *

The circuit clip holds the weight of the tube and allows it to be positioned to meet the needs of patient and clinician. This feature adds stability to the interface and reduces the chances of it pulling off the face.

This product is to be used with the MR850 humidifier, and is compatible with Fisher & Paykel Healthcare's range of interfaces, including:

F&P Visairo™
NIV Mask



RT077X



RT075X

F&P Nivairo™
NIV Mask



RT047X



RT045X

F&P Optiflow™ 3S
NHF Interface



OPT104X

F&P Optiflow+
NHF Interface



OPT94X

Product/Reorder Codes

Part No.	Description	Quantity
850A61J	F&P 850 AirSpiral Adult NIV and NHF circuit kit	10/box

References

1. Thille AW, Muller G, Gacouin A, et al. Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial. *JAMA*. 2019 Oct 15;322(15):1465-1475. 2. Spoletini G, Mega C, Pisani L, et al. High-flow nasal therapy vs standard oxygen during breaks off noninvasive ventilation for acute respiratory failure: A pilot randomized controlled trial. *J Crit Care*. 2018 Dec;48:418-425.

3. Hernández G, Vaquero C, González P, Subira C, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. *JAMA*. 2016 Apr 5;315(13):1354-61. 4. Bell N, Hutchinson CL, Green TC, et al. Randomised control trial of humidified high flow nasal cannulae versus standard oxygen in the emergency department. *Emerg Med Australas*. 2015 Dec;27(6):537-541. 5. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*. 2015 Jun 4;372(23):2185-96.

6. Stéphan F, Barrucand B, Petit P, et al. High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. *JAMA*. 2015 Jun 16;313(23):2331-9. 7. Maggiore SM, Idone FA, Vaschetto R, et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med*. 2015 Dec;27(6):537-541. 8. Peters SG, Holets SR, Gay PC. High-flow nasal cannula therapy in do-not-intubate patients with hypoxemic respiratory distress. *Respir Care*. 2013 Apr;58(4):597-600.

9. Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. *Intensive Care Med*. 2011 Nov;37(11):1780-6. 10. Parke RL, McGuinness SP, Eccleston ML. A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients. *Respir Care*. 2011 Mar;56(3):265-70. 11. Corley A, Caruana LR, Barnett AG, et al. Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. *Br J Anaesth*. 2011 Dec;107(6):998-1004.

* Compared with F&P RT219 and RT319 heated conventional circuits during internal testing.

F&P, AirSpiral, Visairo, Nivairo and Optiflow are all trademarks of Fisher & Paykel Healthcare Limited. For patent information, please see www.fphcare.com/ip.

PM-627168 REV A © 2022

Fisher & Paykel Healthcare Limited